ARGX vs VRTX: How ARGX and Vertex Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARGX and VRTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARGX and VRTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025.

Full ARGX guide

Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.

Full VRTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARGX drivers: Vyvgart franchise momentum; Label and indication expansion.
• VRTX drivers: A durable, high-margin cystic fibrosis near-monopoly; Journavx opens a large non-opioid pain market.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. For VRTX, the central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARGX if you believe its drivers more; VRTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARGX and VRTX guides.

ARGX. argenx trades as a high-growth, richly valued biotech rather than on trailing earnings multiples, with the roughly $47 billion market cap reflecting expectations for continued Vyvgart expansion and pipeline success. The company is now profitable and self-funding, a meaningful shift from the cash-burning profile common to development-stage biotech. Figures are approximate and reflect data available around May 2026.

VRTX. Vertex trades at a premium to the large-cap pharma average, with a trailing P/E near the high 20s and a forward P/E around 25, reflecting both its high margins and near-monopoly economics in cystic fibrosis and the market's expectation that the pain, cell-therapy, and pipeline programs will add a second and third growth engine. Because the CF franchise is so profitable and the balance sheet holds substantial net cash, much of the valuation debate is about how much credit to give unproven pipeline assets. Vertex does not pay a dividend, so returns depend entirely on earnings growth and multiple, which makes clinical and launch execution the key swing factors.

Headline figures (approximate, May 2026): ARGX shows revenue (2025 product net sales) ~$4.15B, revenue growth (2025 yoy) ~90%, q1 2026 net sales ~$1.3B (+63% YoY), q1 2026 profit ~$366M; VRTX shows revenue (fy 2025) ~$12.0 billion, revenue growth (fy 2025) ~9%, revenue guidance (fy 2026) ~$12.95 billion to $13.1 billion, trailing p/e (approx.) ~29x.

ARGX and VRTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARGX and VRTX exposure against your real portfolio. It is not an investment adviser.